“`html
On October 23, 2025, JP Morgan Cazenove reiterated its Underweight recommendation for GSK plc – Depositary Receipt (NYSE:GSK). The average one-year price target for GSK is $44.36, suggesting a potential upside of 2.59% from the latest closing price of $43.24/share.
As of September 30, 2025, GSK’s projected annual revenue is $31,763 million, indicating a growth of 0.42%. There are currently 1,053 funds reporting positions in GSK, with institutional ownership increasing by 3.52% to 486,522K shares over the last three months. The put/call ratio stands at 0.85, reflecting a bullish sentiment among investors.
Significant investors like Dodge & Cox have increased their holdings slightly by 0.13%, while Fisher Asset Management and Primecap Management reported increases of 4.17% and 7.28%, respectively, in their GSK allocations.
“`
